Taro Pharmaceutical Industries (NYSE:TARO) Sees Unusually-High Trading Volume

Taro Pharmaceutical Industries Ltd. (NYSE:TAROGet Rating) shares saw strong trading volume on Tuesday . 2,252 shares changed hands during mid-day trading, a decline of 96% from the previous session’s volume of 58,125 shares.The stock last traded at $36.50 and had previously closed at $36.60.

Separately, StockNews.com downgraded shares of Taro Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, June 7th.

The company’s 50 day moving average price is $37.64 and its 200 day moving average price is $43.76. The company has a market cap of $1.37 billion, a price-to-earnings ratio of 23.61 and a beta of 0.73.

Taro Pharmaceutical Industries (NYSE:TAROGet Rating) last issued its quarterly earnings results on Thursday, May 26th. The company reported $0.73 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.88 by ($0.15). The company had revenue of $143.26 million for the quarter, compared to analyst estimates of $147.00 million. Taro Pharmaceutical Industries had a return on equity of 7.10% and a net margin of 10.38%. During the same quarter last year, the company earned $0.81 EPS. On average, equities analysts forecast that Taro Pharmaceutical Industries Ltd. will post 3.86 EPS for the current fiscal year.

A number of institutional investors have recently added to or reduced their stakes in TARO. Quadrant Capital Group LLC lifted its position in Taro Pharmaceutical Industries by 362.5% during the 4th quarter. Quadrant Capital Group LLC now owns 629 shares of the company’s stock valued at $32,000 after purchasing an additional 493 shares during the period. Harel Insurance Investments & Financial Services Ltd. acquired a new position in Taro Pharmaceutical Industries during the 4th quarter valued at about $45,000. Signaturefd LLC lifted its position in Taro Pharmaceutical Industries by 153.9% during the 4th quarter. Signaturefd LLC now owns 1,526 shares of the company’s stock valued at $76,000 after purchasing an additional 925 shares during the period. Mitsubishi UFJ Trust & Banking Corp lifted its position in Taro Pharmaceutical Industries by 141.7% during the 1st quarter. Mitsubishi UFJ Trust & Banking Corp now owns 2,900 shares of the company’s stock valued at $125,000 after purchasing an additional 1,700 shares during the period. Finally, American Century Companies Inc. lifted its position in Taro Pharmaceutical Industries by 11.0% during the 4th quarter. American Century Companies Inc. now owns 5,005 shares of the company’s stock valued at $251,000 after purchasing an additional 494 shares during the period. Institutional investors own 12.28% of the company’s stock.

About Taro Pharmaceutical Industries (NYSE:TARO)

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products.

Featured Articles

Want More Great Investing Ideas?

Receive News & Ratings for Taro Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.